Scarica l'app Stockscreener
3.76
3.96%
-0.155
Dopo l'orario di chiusura:
3.76
Arcadia Biosciences Inc Borsa (RKDA) Ultime notizie
Arcadia Biosciences (RKDA) Announces Date of Third Quarter 2024 Financial Results and Business Highlights Conference Call - Quantisnow
Zacks Industry Outlook Highlights Bunge, West Fraser Timber, Hydrofarm and Arcadia Biosciences - Yahoo Finance
Arcadia Biosciences stock hits 52-week high at $4 - Investing.com India
Arcadia Biosciences stock hits 52-week high at $4 By Investing.com - Investing.com South Africa
Resistant Starch Market: 2024 Global Future Scope, - openPR
ARDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ardelyx, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Simplify Asset Management Inc. Buys 248,000 Shares of Ardelyx, Inc. (NASDAQ:ARDX) - MarketBeat
ARCA biopharma (NASDAQ:ABIO) Earns Sell Rating from Analysts at StockNews.com - Defense World
Ares Capital Co. (NASDAQ:ARCC) Receives $21.71 Consensus PT from Brokerages - Defense World
Seven Eight Capital LP Trims Stock Holdings in Ardelyx, Inc. (NASDAQ:ARDX) - Defense World
WINTON GROUP Ltd Sells 14,344 Shares of Acadia Healthcare Company, Inc. (NASDAQ:ACHC) - Defense World
Arcellx Sees Unusually Large Options Volume (NASDAQ:ACLX) - Defense World
Ardelyx (NASDAQ:ARDX) Trading Down 3.6% - Defense World
Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 3.5% - Defense World
Arko gains for a second day after report it's mulling sale of convenience stores - Seeking Alpha
Metric Deep Dive: Understanding Ares Capital Corp (ARCC) Through its Ratios - The Dwinnex
Aclaris Therapeutics (NASDAQ:ACRS) Receives “Neutral” Rating from HC Wainwright - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of “Buy” from Brokerages - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Acadia Healthcare Company, Inc.ACHC - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming DeadlinesARDX - PR Newswire
Aclaris Therapeutics (NASDAQ:ACRS) Receives "Neutral" Rating from HC Wainwright - MarketBeat
First Week of January 2027 Options Trading For Ares Capital (ARCC) - Nasdaq
Ares Capital Co. (NASDAQ:ARCC) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Ares Capital (ARCC) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Arcturus Therapeutics Holdings Inc (ARCT) expanding its growth trajectory ahead - SETE News
R1.3bn start to ARC’s financial year - Moneyweb
ARC Investments firms over 4% on strong portfolio growth - Moneyweb
Here's Why Investors Should Invest in Arcturus Stock Now - Zacks Investment Research
Recent Insider Activity Suggests Potential Gains for Arcutis Biotherapeutics Inc (ARQT) - Knox Daily
ARDX Investors Have Opportunity to Lead Ardelyx, Inc.Securities Fraud Lawsuit with the Schall Law Firm - Stockhouse Publishing
Arcturus Therapeutics Holdings Inc [ARCT] Insider Activity: An Update for Investors - Knox Daily
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of “Buy” by Brokerages - Defense World
ACHC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Acadia Healthcare Company, Inc. and Encourages Investors to Contact the Firm! - PR Newswire
Amendment: Arcadia Biosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits - Quantisnow
Wheat no longer in Arcadia’s future - Food Business News
Analysts Offer Predictions for Arcadia Biosciences, Inc.’s Q3 2024 Earnings (NASDAQ:RKDA) - Defense World
Arcadia shifting focus away from wheat - World Grain
Arcadia’s future no longer includes wheat - BakingBusiness.com
SPANISH COPY APPROVAL INTERACTIVE MEDIA SCHEDULED TEST Esheet # 54112387 / 5528413c - Business Wire
SEC Form 4 filed by Director Yoder Amy - Quantisnow
SEC Form 4 filed by Director Comcowich Kevin - Quantisnow
Arcadia Biosciences CEO acquires $1,442 in company stock By Investing.com - Investing.com Australia
Arcadia Biosciences CFO acquires $1.4k in company stock By Investing.com - Investing.com Australia
HC Wainwright Reiterates “Buy” Rating for Arcadia Biosciences (NASDAQ:RKDA) - Defense World
Arcadia Biosciences CFO acquires $1.4k in company stock - Investing.com India
Arcadia Biosciences CEO acquires $1,442 in company stock - Investing.com India
Chief Financial Officer Kawakami Mark bought $1,442 worth of shares (700 units at $2.06), increasing direct ownership by 55% to 1,981 units (SEC Form 4) - Quantisnow
Chief Executive Officer Schaefer Thomas J. bought $1,442 worth of shares (700 units at $2.06), increasing direct ownership by 49% to 2,119 units (SEC Form 4) - Quantisnow
Arcadia Biosciences (NASDAQ:RKDA) Stock, Analyst Ratings, Price Targets, Forecasts - Benzinga
Arcadia Biosciences (STU:17D) Owner Earnings per Share (TTM) : -5.91 (As of Jun. 2024) - GuruFocus.com
Arcadia Biosciences (RKDA) to Participate in Upcoming Investor Conferences - Marketscreener.com
Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q2 2024 Earnings Call Transcript - Insider Monkey
Arcadia Biosciences (RKDA) Q2 Earnings Miss, Increase Y/Y - MSN
Arcadia Biosciences (NASDAQ:RKDA) Posts Earnings Results, Misses Expectations By $0.49 EPS - Defense World
Earnings call: Arcadia Biosciences sees growth in Zola, streamlines operations - Investing.com Australia
Arcadia Biosciences Inc (RKDA) Q2 2024 Earnings Call Transcript - GuruFocus.com
Arcadia Biosciences: Q2 Earnings Snapshot - Darien Times
RKDA Stock Earnings: Arcadia Biosciences Misses EPS, Beats Revenue for Q2 2024 - InvestorPlace
2.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):